KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.

Ravindra Uppaluri, Douglas R. Adkins, Stéphane Temam et al.|Journal of Clinical Oncology|2019

Cited by 51